FDA Clears AI Guidance Tool for Mitral Repair
AI enhances real-time intraprocedural visualization and navigation.
By
Kathryn Wighton
March 26, 2026
Clinical Scorecard: FDA Clears AI Guidance Tool for Mitral Repair
At a Glance
Category Detail
Condition Mitral Regurgitation Key Mechanisms Real-time visualization and tracking of mitral transcatheter edge-to-edge repair devices. Target Population Adults with mitral regurgitation, affecting over 35 million globally and 2 million in the US. Care Setting Minimally invasive cardiac procedures.
Key Highlights
AI-enabled software assists in minimally invasive mitral valve repair. Integrates with Philips Azurion platform for enhanced imaging. Reduces manual adjustments and improves procedural workflow. Developed in collaboration with Edwards Lifesciences. Maintains physician control while enhancing team communication. Guideline-Based Recommendations
Diagnosis
Utilize echocardiography for assessment of mitral regurgitation. Management
Consider transcatheter approaches for suitable patients. Monitoring & Follow-up
Continuous assessment of device position during procedures. Risks
Procedures remain technically complex and require precise coordination. Patient & Prescribing Data
Adults with mitral regurgitation eligible for minimally invasive repair.
AI technology enhances precision and reduces unnecessary imaging adjustments.
Clinical Best Practices
Ensure integration of imaging and device data for procedural efficiency. Maintain clear communication across the interventional heart team. Related Resources & Content
